In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Shares of Eli Lilly & Co. LLY rallied 1.34% to $771.71 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.01% to 6,296.79 and ...

3. Justifying its valuation with its outlook Eli Lilly's valuation might be a significant stumbling block for some investors. If the stock fails to meet the market's lofty expectations, its shares ...

Key Points President Trump has threatened to levy tariffs of up to 200% on pharmaceutical imports.Lilly's margins could be negatively affected if the company absorbs the higher costs.However, any ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.

Prime Medicine (NASDAQ:PRME) stock rose 32%, extending recent gains following Eli Lilly’s (NYSE:LLY) acquisition deal for Verve Therapeutics (NASDAQ:VERV) last month.

Shares of Eli Lilly & Co. LLY slid 2.47% to $775.45 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.52% to 6,173.07 ...

Eli Lilly and Company (NYSE:LLY) is one of the most frequently discussed stocks on Cramer’s morning show.